NovoCure director granted shares and options

NovoCure Ltd director Allyson J. Ocean received new equity awards.

Rhea-AI Filing Summary

NovoCure Ltd director Allyson J. Ocean received new equity awards. She was granted 11,610 restricted stock units that will vest 100% on the earlier of the first anniversary of the grant or the day immediately preceding the company’s 2027 annual general meeting of shareholders.

She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest on the same schedule and expire on June 3, 2036. Following the restricted stock unit grant, she directly holds 22,934 ordinary shares.

Insider Trade Summary

Grant/Award: 28,609 shares

Grant/Award 2 txns

Insider Ocean Allyson J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,999	$0.00	$0.00
Grant/Award	Ordinary Shares	11,610	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,999 contracts (Direct); Ordinary Shares — 22,934 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
2. F2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Key Figures

Restricted stock units granted: 11,610 units Shares held after grant: 22,934 ordinary shares Stock options granted: 16,999 options +3 more

6 metrics

Restricted stock units granted 11,610 units Award to director Allyson J. Ocean on June 3, 2026

Shares held after grant 22,934 ordinary shares Direct holdings following RSU award

Stock options granted 16,999 options Right to buy ordinary shares, granted June 3, 2026

Option exercise price $16.15 per share Strike price for 16,999 stock options

Option expiration date June 3, 2036 Expiration of granted stock options

RSU vesting trigger First anniversary or pre-2027 AGM 100% vest when either condition is met

Key Terms

restricted stock units, Stock Option (Right to Buy, annual general meeting of shareholders, exercise price

4 terms

restricted stock units financial

"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy financial

"Stock Option (Right to Buy)"

annual general meeting of shareholders financial

"the day immediately preceding the Company's 2027 annual general meeting of shareholders"

exercise price financial

"Options to buy ordinary shares will fully vest and become exercisable"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovoCure (NVCR) director Allyson J. Ocean report in this Form 4?

Director Allyson J. Ocean reported equity awards, not open-market trades. She received 11,610 restricted stock units and options for 16,999 ordinary shares, all granted as compensation, increasing her direct ownership position in NovoCure through stock-based awards rather than purchases or sales.

How many NovoCure (NVCR) shares does Allyson J. Ocean now hold directly?

After the latest restricted stock unit award, Allyson J. Ocean directly holds 22,934 ordinary shares of NovoCure. This figure reflects her position following the grant of 11,610 restricted stock units reported in the filing and provides context for the scale of the new award.

What are the vesting terms of Allyson J. Ocean’s NovoCure restricted stock units?

The 11,610 restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. This structure ties vesting to either a time-based or meeting-based milestone.

What are the details of the NovoCure stock options granted to Allyson J. Ocean?

She was granted options to buy 16,999 ordinary shares at an exercise price of $16.15 per share. These options fully vest on the earlier of the first anniversary of the grant date or the day before the 2027 annual general meeting and expire on June 3, 2036.

Are Allyson J. Ocean’s Form 4 transactions in NovoCure shares open-market buys or sells?

The Form 4 shows compensation-related acquisitions, not open-market trades. Both reported transactions use code A, indicating grants or awards of restricted stock units and stock options, rather than discretionary purchases or sales in the public market by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ocean Allyson J

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/03/2026		A		11,610	A	$0.00	22,934	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.15	06/03/2026		A		16,999		06/03/2027(2)	06/03/2036	Ordinary Shares	16,999	$0.00	16,999	D

Explanation of Responses:

1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Remarks:

	Steven Robbins, as attorney in fact for Ocean, Allyson J.	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)